Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$17.4K Buy
48
+7
+17% +$2.4K ﹤0.01% 77
2026
Q1
$14.4K Hold
41
﹤0.01% 75
2025
Q4
$13.4K Buy
41
+25
+156% +$7.93K ﹤0.01% 78
2025
Q3
$4.51K Sell
16
-7
-30% -$2.03K ﹤0.01% 99
2025
Q2
$6.42K Buy
23
+2
+10% +$567 ﹤0.01% 93
2025
Q1
$6.54K Buy
21
+14
+200% +$4.13K ﹤0.01% 86
2024
Q4
$1.82K Buy
7
+1
+17% +$297 ﹤0.01% 104
2024
Q3
$1.93K Sell
6
-1
-14% -$327 ﹤0.01% 95
2024
Q2
$2.19K Sell
7
-2
-22% -$588 ﹤0.01% 85
2024
Q1
$2.56K Buy
9
+1
+13% +$293 ﹤0.01% 81
2023
Q4
$2.3K Hold
8
﹤0.01% 86
2023
Q3
$2.15K Buy
+8
New +$2K ﹤0.01% 81
2023
Q1
Sell
-6
Closed -$1.47K 86
2022
Q4
$1.58K Sell
6
-1
-14% -$268 ﹤0.01% 82
2022
Q3
$2K Hold
7
﹤0.01% 81
2022
Q2
$1.7K Buy
+7
New +$1.72K ﹤0.01% 89
2022
Q1
Sell
-4
Closed -$919 94
2021
Q4
$899 Buy
+4
New +$844 ﹤0.01% 118
2021
Q3
Hold
0
105
2021
Q2
Hold
0
90
2014
Q1
Sell
-572,351
Closed -$65.3M 33
2013
Q4
$65.3M Sell
572,351
-144,928
-20% -$16.5M 2.36% 22
2013
Q3
$80.3M Sell
717,279
-53,109
-7% -$5.76M 2.63% 22
2013
Q2
$76M Buy
+770,388
New +$79.9M 2.5% 22

Other funds holding AMGN

WestEnd Advisors's AMGN Position: Q2 2026 in Review

WestEnd Advisors increased its Amgen (AMGN) stake by 17% in Q2 2026, buying an estimated $2.4K and bringing the position to 48 shares worth $17.4K. The position accounts for ﹤0.01% of the portfolio, ranked #77.

WestEnd Advisors first reported a position in AMGN in Q2 2013 and has held it in 19 quarters since. The position peaked at $80.3M in Q3 2013. 1,055 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • WestEnd Advisors held 48 shares of Amgen worth $17.4K as of Q2 2026.
  • WestEnd Advisors bought 7 Amgen shares in Q2 2026, an estimated $2.4K.
  • Amgen made up ﹤0.01% of WestEnd Advisors's portfolio in Q2 2026, its #77 holding.
  • WestEnd Advisors first reported a position in Amgen in Q2 2013 and has held it in 19 quarters since.
  • WestEnd Advisors's Amgen position peaked at $80.3M in Q3 2013.
  • 1,055 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on WestEnd Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.